Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
Regulatoryapprovedivonescimab injectionPositive
AI Analysis
Summary
Akeso's ivonescimab in combination with chemotherapy received NMPA approval for first-line treatment of squamous NSCLC, establishing a new treatment standard. The HARMONi-6 trial data supports this regulatory milestone in lung cancer therapy.
Clinical Trial Data
Outcome Details
NMPA approved supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy for first-line squamous NSCLC
Importance:8/10
Sentiment:
0.85
lung cancerNSCLCimmunotherapyChina approvalNMPAcombination therapy
Related Companies
Read the original article
Published by PR Newswire Biotech on August 12, 2026 12:17 PM